Table 3. Percentage of Patients with Clinical Features of MEN2 by Subtype
| Subtype | Medullary Thyroid Carcinoma (%)a | Pheochromocytoma (%)a | Parathyroid Disease (%)a |
| MEN2A | 95 | 50 | 15–30 |
| FMTC | ~100 | 0 | 0 |
| MEN2B | 100 | 50 | Uncommon |
| FMTC = familial medullary thyroid carcinoma; MEN2 = multiple endocrine neoplasia type 2. | |||
| aPercentages based on observations in referral populations.[5-9] |
References
- Eng C: Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 335 (13): 943-51, 1996. [PUBMED Abstract]
- Gagel RF, Tashjian AH Jr, Cummings T, et al.: The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 318 (8): 478-84, 1988. [PUBMED Abstract]
